Ghana is broadening its HIV prevention strategy by making pre-exposure prophylaxis (PrEP) tablets available to people at elevated risk of infection, according to a report from Adomonline.com published on Wednesday, August 26, 2026.
The move, as detailed by the outlet, aims to give higher-risk individuals a daily preventive option to reduce their chances of contracting HIV. Adomonline.com did not specify which groups qualify as high-risk or provide details on distribution channels, but the expansion signals a shift toward more targeted prevention tools in the country's broader HIV response.
PrEP is a proven biomedical intervention that, when taken consistently, significantly lowers the likelihood of HIV transmission. Ghana's decision to widen access aligns with global public health guidance that encourages making the tablets available to populations where infection rates remain elevated, such as sex workers, men who have sex with men, and individuals with HIV-positive partners. The report from Adomonline.com did not include specific figures on current HIV prevalence in Ghana or the number of people expected to receive the tablets.
The announcement follows a pattern of increasing emphasis on combination prevention—pairing PrEP with condom use, testing, and treatment access—rather than relying on behavioral messaging alone. Adomonline.com's coverage suggests the tablets will be integrated into existing health services, though logistical specifics, including cost and availability in rural areas, were not disclosed in the report.
What to watch next: Whether Ghana's health authorities will publish detailed rollout targets or eligibility criteria in the coming weeks, and how the program's uptake compares to other West African nations expanding PrEP access.